ScanSource, Inc. (SCSC) SEC Filings & Earnings Calls
EquiReason read 13 ScanSource, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-02 — ScanSource completed acquisition of MicroAge for $220.5M cash, funded via credit facility. Expected to be accretive to margins and EPS in first year..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.2B
- P/E TTM
- 16.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Sep 20268-K · 2.03, 7.01ScanSource completed acquisition of MicroAge for $220.5M cash, funded via credit facility. Expected to be accretive to margins and EPS in first year.acquisitionopen
Figures in the filing · each found in the filing text
| Purchase price · Q1-2027 | $221M | |
| Borrowings under revolving credit facility · Q1-2027 | $225M |
Guidance
Acquisition expected to be accretive to gross profit margin, adjusted EBITDA margin, and non-GAAP EPS in first year; free cash flow positive.
Risks flagged
Integration risk: ability to successfully integrate MicroAge and realize expected benefits.
“the ability of the Company to successfully integrate MicroAge into its business and the risk that the Company will fail to realize the expected benefits of the acquisition” · word for word
20 Aug 202610-KSCSC reported FY2026 results with total net sales +6.1% YoY, operating income +15.8% YoY, and non-GAAP EPS +18.8% YoY.earningsopen
Figures in the filing · each found in the filing text
| Total net sales · FY2026 | $3.23B | +6% y/y |
| Specialty Technology Solutions net sales · Specialty Technology Solutions · FY2026 | $3.12B | +6% y/y |
| Intelisys & Advisory net sales · Intelisys & Advisory · FY2026 | $101M | +3% y/y |
| Specialty Technology Solutions gross profit margin · Specialty Technology Solutions · FY2026 | 10.8% | |
| Intelisys & Advisory gross profit margin · Intelisys & Advisory · FY2026 | 98.6% | |
| Total gross profit · FY2026 | $437M | +7% y/y |
| Total operating income · FY2026 | $99M | +16% y/y |
| Net income · FY2026 | $79M | +10% y/y |
| Operating cash flow · FY2026 | $123M | +10% y/y |
| Adjusted EBITDA · FY2026 | $152M | +5% y/y |
Guidance
FY2027 capex guided $8M-$12M
Management provided capex guidance for FY2027 and expressed confidence in liquidity, but no explicit revenue or earnings guidance.
Risks flagged
Supplier concentration risk
“A significant percentage of our net sales relates to products we purchase from relatively few suppliers, including Cisco and Zebra.”
Supply chain disruption risk
“Specifically, shortages of computer chips may lead to product constraints and adversely affect our sales volumes and product availability.” · word for word
International operations risk
“International net sales, reported ... (13,467) ... (5.6)% ... constant currency ... (12.7)%”
Credit risk from channel sales partners
“We have credit exposure to our channel sales partners. Any adverse trends or significant adverse incidents in their businesses could cause us to suffer credit losses.” · word for word
Goodwill impairment risk
“The fair value of the reporting units exceeded its carrying value by 2% and more than 100%, respectively, as of the annual goodwill impairment testing date.” · word for word
20 Aug 20268-K · 1.01, 2.02ScanSource Q4 FY26: sales +17% Y/Y to $953M, EPS +41% Y/Y to $1.24, FY26 EPS +21% to $3.64; FY27 outlook: net sales growth 6-10%, adj. EBITDA $158-165M, FCF ≥$85M; also announced MicroAge acquisition.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q4-2026 | $953M | +17% y/y |
| Gross Profit · Consolidated · Q4-2026 | $120M | +14% y/y |
| Gross Profit Margin · Consolidated · Q4-2026 | 12.6% | |
| Operating Income · Consolidated · Q4-2026 | $32M | +18% y/y |
| Net Income · Consolidated · Q4-2026 | $26M | +28% y/y |
| Diluted EPS · Consolidated · Q4-2026 | $1.24 | +41% y/y |
| Non-GAAP Diluted EPS · Consolidated · Q4-2026 | $1.46 | +43% y/y |
| Adjusted EBITDA · Consolidated · Q4-2026 | $46M | +19% y/y |
| Adjusted EBITDA Margin · Consolidated · Q4-2026 | 4.8% | |
| Operating Cash Flow · Consolidated · FY2026 | $123M |
Guidance
FY27 annual outlook: Net Sales Growth Y/Y 6% to 10%; Adjusted EBITDA $158 million to $165 million; Free Cash Flow at least $85 million
FY27 guidance implies continued growth with 6-10% sales growth and EBITDA $158-165M
Risks flagged
Macroeconomic risks including tariffs and trade policy changes
“macroeconomic conditions, including potential prolonged economic weakness, inflation, tariffs and changes in trade policy” · word for word
Integration risk from MicroAge acquisition
“the ability for ScanSource to realize the synergies or other benefits from acquisitions” · word for word
Credit risk from channel partners
“credit risks involving ScanSource's larger channel sales partners and suppliers” · word for word
Cybersecurity and IT system failure risk
“risk to the business from a cyberattack, a failure of IT systems” · word for word
17 Aug 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
Minimal risk; routine board retirement
“no disagreement”
29 May 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of CIO may disrupt IT strategy and transformation initiatives.
“Role elimination of Senior EVP and Chief Information Officer.”
7 May 202610-QNet Sales $767M (+9% y/y); Net Sales - Specialty Technology Solutions $741M (+9% y/y); Net Sales - Intelisys & Advisory $26M (-2% y/y); Guidance: Capex guided $8M-$10M for FY2026; effective tax rate 27.9%-28.2%open
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q3-2026 | $767M | +9% y/y |
| Net Sales - Specialty Technology Solutions · Specialty Technology Solutions · Q3-2026 | $741M | +9% y/y |
| Net Sales - Intelisys & Advisory · Intelisys & Advisory · Q3-2026 | $26M | -2% y/y |
| Gross Profit · Consolidated · Q3-2026 | $107M | +7% y/y |
| Gross Margin · Consolidated · Q3-2026 | 14.0% | |
| Operating Income · Consolidated · Q3-2026 | $23M | +4% y/y |
| Net Income · Consolidated · Q3-2026 | $17M | -3% y/y |
| Adjusted EBITDA · Consolidated · Q3-2026 | $36M | +2% y/y |
| Operating Cash Flow · Consolidated · 9M-2026 | $125M | +20% y/y |
| Adjusted ROIC · Consolidated · Q3-2026 | 14.3% |
Guidance
Capex guided $8M-$10M for FY2026; effective tax rate 27.9%-28.2%
Management reaffirms ability to pass through tariff costs; capex and tax rate guidance provided.
Risks flagged
Tariff and Trade Policy Uncertainty
“The macroeconomic environment, including the economic impacts of growth outlook, inflationary pressures, tariffs and evolving geopolitical conflicts and trade relationships, continues to create significant uncertainty and may adversely affect our financial condition and results of operations.” · word for word
Customer Concentration
“credit risks involving the Company's larger channel sales partners and suppliers” · word for word
7 May 20268-K · 2.02Net sales $767M (+9% y/y); Gross profit $107M (+7% y/y); Operating income $23M (+4% y/y); Guidance: Free Cash Flow raised to at least $90Mearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2026 | $767M | +9% y/y |
| Gross profit · Q3-2026 | $107M | +7% y/y |
| Operating income · Q3-2026 | $23M | +4% y/y |
| Net income · Q3-2026 | $17M | -3% y/y |
| Adjusted EBITDA · Q3-2026 | $36M | +2% y/y |
| STS Net Sales · Specialty Technology Solutions · Q3-2026 | $741M | +9% y/y |
| I&A Net Sales · Intelisys & Advisory · Q3-2026 | $26M | -2% y/y |
| Non-GAAP diluted EPS · Q3-2026 | $0.94 | +9% y/y |
Guidance
Free Cash Flow raised to at least $90M
Raised free cash flow outlook; maintained revenue and EBITDA guidance.
Risks flagged
Macroeconomic risks including tariffs and trade policy changes; net income slightly down.
“Forward-looking statements mention tariffs and trade policy risks.”
5 Feb 20268-K · 2.02, 7.01Net sales $767M (+2% y/y); GAAP diluted EPS $0.75 (+7% y/y); Adjusted EBITDA $31M (-12% y/y); Guidance: Net sales lowered to $3.0-3.1B from $3.1-3.3B; Adjusted EBITDA lowered to $140-150M from $150-160Mearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $767M | +3% y/y |
| GAAP diluted EPS · Q2-2026 | $0.75 | +7% y/y |
| Adjusted EBITDA · Q2-2026 | $31M | -12% y/y |
| Adjusted EBITDA margin · Q2-2026 | 4.1% | |
| Non-GAAP diluted EPS · Q2-2026 | $0.80 | -6% y/y |
| Recurring revenue growth · Q2-2026 | 15.9% | |
| Free cash flow · H1-2026 | $50M | |
| FY2026 free cash flow guidance · FY2026 | $80M |
Guidance
Net sales lowered to $3.0-3.1B from $3.1-3.3B; Adjusted EBITDA lowered to $140-150M from $150-160M
FY2026 guidance lowered for both net sales and Adjusted EBITDA, though free cash flow guidance maintained. Management remains committed to three-year strategic goals.
Risks flagged
Guidance cut for both net sales and Adjusted EBITDA indicates weaker-than-expected demand and margin pressure.
“Net sales $3.0 billion to $3.1 billion (prior $3.1 billion to $3.3 billion)... Adjusted EBITDA (non-GAAP) $140 million to $150 million (prior $150 million to $160 million)” · word for word
Gross profit margin declined 18 bps YoY, indicating competitive pressure.
“Gross profit margin % 13.4% vs 13.6% prior year, -18bp”
5 Feb 202610-QScanSource reported Q2 FY2026 results: consolidated net sales +2.5% YoY, GAAP operating income -3.1% YoY, with mixed segment performance and tariff/freight headwinds.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q2-2026 | $767M | +3% y/y |
| Net Sales · Consolidated · H1-2026 | $1.51B | -1% y/y |
| Net Sales - Specialty Technology Solutions · Specialty Technology Solutions · Q2-2026 | $742M | +3% y/y |
| Net Sales - Intelisys & Advisory · Intelisys & Advisory · Q2-2026 | $25M | +3% y/y |
| Gross Profit · Consolidated · Q2-2026 | $103M | +1% y/y |
| Gross Margin · Consolidated · Q2-2026 | 13.4% | |
| Operating Income · Consolidated · Q2-2026 | $18M | -3% y/y |
| Net Income · Consolidated · Q2-2026 | $16M | -3% y/y |
| Adjusted EBITDA · Consolidated · Q2-2026 | $31M | -12% y/y |
| Adjusted ROIC · Consolidated · Q2-2026 | 11.9% |
Guidance
FY2026 capex guided $8M-$12M; effective tax rate 27.2%-28.2%
Management provided capex guidance of $8M-$12M for FY2026 and effective tax rate guidance of 27.2%-28.2%, but did not provide explicit revenue or earnings guidance.
Risks flagged
Tariff and Trade Policy Uncertainty
“The macroeconomic environment, including the economic impacts of growth outlook, inflationary pressures, tariffs and evolving geopolitical and trade relationships, continues to create significant uncertainty and may adversely affect our financial condition and results of operations.” · word for word
Freight Cost Pressure on Gross Margin
“Higher freight costs reduced gross profit by $2.1 million for the quarter.” · word for word
Brazil Revenue Decline
“Brazil net sales decreased 2.1% for the quarter and 5.9% for the six months; constant currency decline of 9.4% and 10.4% respectively.”
Customer Bad Debt in Brazil
“SG&A includes customer specific bad debt expenses in Brazil for the quarter and six months ended December 31, 2025.” · word for word
19 Dec 20258-K · 1.01, 1.02, 2.03Revolving credit facility $400M; term loan facility $100Mopen
Figures in the filing · each found in the filing text
| revolving credit facility · Q4-2025 | $400M | |
| term loan facility · Q4-2025 | $100M |
Risks flagged
Leverage ratio covenant: must be ≤ 3.50x; interest coverage ≥ 3.00x.
“Leverage ratio must be less than or equal to 3.50 to 1.00; Interest Coverage Ratio at least 3.00:1.00.” · word for word
6 Nov 202510-QScanSource reported Q1 FY2026 results: consolidated net sales declined 4.6% YoY, but gross margin expanded and operating income grew 46.9% YoY.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q1-2026 | $740M | -5% y/y |
| Net Sales - Specialty Technology Solutions · Specialty Technology Solutions · Q1-2026 | $715M | -5% y/y |
| Net Sales - Intelisys & Advisory · Intelisys & Advisory · Q1-2026 | $24M | +4% y/y |
| Gross Profit Margin - Specialty Technology Solutions · Specialty Technology Solutions · Q1-2026 | 11.7% | |
| Operating Income - Specialty Technology Solutions · Specialty Technology Solutions · Q1-2026 | $20M | +22% y/y |
| Operating Income - Intelisys & Advisory · Intelisys & Advisory · Q1-2026 | $6M | -9% y/y |
| Adjusted EBITDA · Consolidated · Q1-2026 | $39M | |
| Adjusted Return on Invested Capital (annualized) · Consolidated · Q1-2026 | 14.6% | |
| Cash and Cash Equivalents · Consolidated · 2025-09-30 | $125M | |
| Days Sales Outstanding · Consolidated · 2025-09-30 | 68 |
Risks flagged
Tariff and Trade Policy Uncertainty
“The macroeconomic environment, including the economic impacts of growth outlook, inflation, tariffs and shifting relations between the U.S. and other countries, continues to create significant uncertainty and may adversely affect our financial condition and results of operations.” · word for word
Demand Weakness in Specialty Technology Solutions
“For the quarter ended September 30, 2025, net sales decreased primarily due to lower large deals.” · word for word
6 Nov 20258-K · 2.02Net Sales $740M (-5% y/y); Gross Profit $107M (+6% y/y); Adjusted EBITDA $39M (+8% y/y); Guidance: Net Sales $3.1B-$3.3B, Adjusted EBITDA $150M-$160M, Free Cash Flow at least $80Mearningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q1-2026 | $740M | -5% y/y |
| Gross Profit · Consolidated · Q1-2026 | $107M | +6% y/y |
| Adjusted EBITDA · Consolidated · Q1-2026 | $39M | +8% y/y |
| GAAP Diluted EPS · Consolidated · Q1-2026 | $0.89 | +29% y/y |
| Non-GAAP Diluted EPS · Consolidated · Q1-2026 | $1.06 | +26% y/y |
| Free Cash Flow · Consolidated · Q1-2026 | $21M | |
| Operating Cash Flow · Consolidated · Q1-2026 | $23M | |
| STS Net Sales · Specialty Technology Solutions · Q1-2026 | $715M | -5% y/y |
| STS Gross Profit · Specialty Technology Solutions · Q1-2026 | $84M | +7% y/y |
| I&A Net Sales · Intelisys & Advisory · Q1-2026 | $24M | +4% y/y |
Guidance
Net Sales $3.1B-$3.3B, Adjusted EBITDA $150M-$160M, Free Cash Flow at least $80M
Reaffirmed FY26 annual outlook with double-digit EPS growth and strong free cash flow.
Risks flagged
STS sales decline of 5% Y/Y indicates potential demand weakness in core technology distribution.
“STS, Net Sales -5% Y/Y $715M” · word for word
Macroeconomic risks including inflation, tariffs, and trade policy changes could impact future results.
“macroeconomic conditions, including potential prolonged economic weakness, inflation, tariffs and changes in trade policy” · word for word
ScanSource, Inc. — questions
- What did ScanSource, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 8-K on 2026-09-02 — ScanSource completed acquisition of MicroAge for $220.5M cash, funded via credit facility. Expected to be accretive to margins and EPS in first year.
Every figure on this page comes from ScanSource, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.